Cardinal Health Inc

CAH

Add to Watchlist

183.650USD

-1.630-0.88%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

Cardinal Health Inc's Score

Industry at a Glance

Industry Ranking

26 / 156

Overall Ranking

94 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Cardinal Health Inc Highlights

StrengthsRisks

Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 222.58B.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 222.58B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 31.52%.

Fairly Valued

The company’s latest PE is 27.97, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 213.49M shares, decreasing 5.15% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 5.47K shares of this stock.

Analyst Rating

Based on 19 analysts

Buy

Current Rating

245.696

Target Price

+24.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cardinal Health Inc is 8.59, ranking 44 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 60.94B, representing a year-over-year increase of 11.05%, while its net profit experienced a year-over-year increase of 21.15%.

Score

Industry at a Glance

Previous score

8.59

Change

0



Financials

4.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cardinal Health Inc is 5.45, ranking 144 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 27.97, which is 376.84% below the recent high of 133.35 and 162.56% above the recent low of -17.50.

Score

Industry at a Glance

Previous score

5.45

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/156

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cardinal Health Inc is 8.44, ranking 37 out of 156 in the Pharmaceuticals industry. The average price target is 220.00, with a high of 243.00 and a low of 152.11.

Score

Industry at a Glance

Previous score

8.44

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cardinal Health Inc is 6.66, ranking 104 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 206.46 and the support level at 171.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Cardinal Health Inc is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 91.15%, representing a quarter-over-quarter increase of 0.17%. The largest institutional shareholder is The Vanguard, holding a total of 30.41M shares, representing 12.99% of shares outstanding, with 1.18% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

31.33M

+2.01%

BlackRock Institutional Trust Company, N.A.

14.69M

-2.48%

State Street Investment Management (US)

12.51M

+1.80%

Geode Capital Management, L.L.C.

6.53M

+0.68%

Wellington Management Company, LLP

5.17M

-10.98%

Fidelity Management & Research Company LLC

4.23M

-10.11%

BlackRock Financial Management, Inc.

4.22M

-25.81%

WCM Investment Management

4.03M

+685.58%

Norges Bank Investment Management (NBIM)

3.85M

+10.56%

BlackRock Investment Management, LLC

2.73M

-4.26%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cardinal Health Inc is 9.07, ranking 17 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.53. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Cardinal Health Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Cardinal Health Inc

CAH

7.89 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.80 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Collegium Pharmaceutical Inc

COLL

8.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment